CONTRIBUTOR
Managing Editor and Podcast Host,
Techstrong

Synopsis

In this Digital CxO Leadership Insights video interview, Amanda Razani speaks with Gary Shorter, head of AI and data science at IQVIA Technologies, about digital twins, artificial intelligence and data collection in the life sciences industry.

Transcript

In this interview, Amanda Razani, the host of the Leadership Insights video series, speaks with Gary Shorter, head of AI and data science at IQVIA, about the company’s role in the life sciences and health care industry. Gary explains that IQVIA supports pharmaceutical companies in running clinical trials efficiently and safely, utilizing advanced technologies like AI and data science to enhance their capabilities. He highlights the regulatory challenges in this highly controlled industry and the potential benefits and limitations of integrating new AI tools into their processes. Gary discusses the emergence of digital twins, which create virtual models of patient situations to run simulations and optimize therapeutic strategies without involving real humans or animals. This technology is also applied to improve and test operational processes, emphasizing the importance of accurate and reliable data to ensure regulatory compliance.

Further, the conversation delves into the complexities of creating digital twins for individual patients, noting the variability and accessibility of data from different sources like real-world healthcare information, clinical trials, and genomic data. Gary outlines the necessity of collaborating with other entities to build comprehensive models and transparently present their methodologies to regulatory authorities. He envisions the future of the industry, predicting a move towards more specialized, domain-specific AI models and multimodal libraries to handle diverse and complex queries efficiently. Gary stresses the importance of cautiously adopting AI, emphasizing the need for continual human oversight to ensure trustworthy and accurate outcomes while leveraging AI’s potential to drive efficiency and innovation in the life sciences field.